Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1161-1170

  Wade, Alan G ^a   Saragoussi, Delphine ^b   Despiégel, Nicolas ^b   François, Clément ^b   Guelfucci, Florent ^c   Toumi, Mondher ^d  

^a CPS Research   (United Kingdom)

^b Lundbeck   (France)

^c Altipharm   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Antidepressive agents; Escitalopram; GPRD; Healthcare costs; Retrospective studies; Selective serotonin reuptake inhibitors; Severe depression; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; HYPNOTIC AGENT; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEPRESSION; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRESCRIPTION; PRIMARY MEDICAL CARE; PSYCHOPHARMACOTHERAPY; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; CITALOPRAM; CYCLOHEXANOLS; DEPRESSION; DRUGS, GENERIC; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77951030523     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003738519     Document Type: Article

References (46)

1. Hale AS. ABC of mental health. Depression. BMJ 1997;315:43-46
2. Angst J. The epidemiology of depressive disorders. Eur Neuropsychopharmacol 1995;5(Suppl):95-98
3. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627 (Pubitemid 40973437)
4. Huang FY, Chung H, Kroenke K, et al. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med 2006;21:547-552
5. Karasu TB, Gelenberg A, Merriam A, Wang P. American Psychiatric Association practice guidelines for the treatment of patients with major depressive disorder, 2nd edn. Washington, DC: American Psychiatric Press, 2000
6. TM, 2000). 4th edn. Washington, DC: American Psychiatric Association, 2000
7. Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997;12:19-29
8. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001;15:765-776
9. Thompson D, Richardson E. Current issues in the economics of depression management. Curr Psychiatry Rep 1999;1:125-134
10. National Institute for Health and Clinical Excellence. Depression: management of depression in primary and secondary care-NICE guidance. London: National Institute for Health and Clinical Excellence, 2006
11. Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006;39:180-184
12. Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-1341
13. Llorca PM, Azorin JM, Despiegel N, et al. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005;59:268-275
14. Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007;22:323-329
15. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-137
16. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009;25:161-175
17. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-1196
18. Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006;21:297-309
19. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64
20. Kienke AS, Rosenbaum JF. Efficacy of venlafaxine in the treatment of severe depression. Depress Anxiety 2000;12(Suppl 1):50-54
21. Danchenko N, Hansen K, Holsten F, Despiegel N. Cost-effectiveness of esci-talopram versus citalopram and venlafaxine in treatment of severe depression in Norway [abstract]. 6th World Congress on Health Economics (iHEA) 2007; Copenhagen, Denmark, 2007
22. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45:419-425
23. Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330:389
24. Curtis L, Netten A. Unit costs of health and social care 2006. Personal Social Services Research Unit, University of Kent, Canterbury, UK, 2006
25. McKinstry B, Walker J, Campbell C, et al. Telephone consultations to manage requests for same-day appointments: a randomised controlled trial in two practices. Br J Gen Pract 2002;52:306-310
26. Pinnock H, McKenzie L, Price D, et al. Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial. Br J Gen Pract 2005;55:119-124 (Pubitemid 40246925)
27. National Health Service. Hospital Episode Statistics Online
28. WHO Collaborating Centre for Drug Statistics Methodology
29. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253-259
30. Einarson TR, Arikian SR, Casciano J, et al. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepres-sants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999;21:296-308
31. Machado M, Iskedjian M, Ruiz I, et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006;22:1825-1837
32. Shelton C, Entsuah R, Padmanabhan SK, et al. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol 2005;20:233-238
33. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepres-sants: a meta-analysis. Br J Psychiatry 2002;180:396-404
34. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-1174
35. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178:234-241
36. Benkert O, Grunder G, Wetzel H, et al. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996;30:441-451
37. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9:139-143
38. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
39. Zanardi R, Franchini L, Serretti A, et al. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 2000;61:26-29
40. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008; 63:424-434
41. Weinmann S, Becker T, Koesters M. Re-evaluation of the efficacy and toler-ability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl) 2008;196:511-520
42. Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escita-lopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005;27:486-496
43. Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005; 21:631-642
44. Sorensen J, Stage KB, Damsbo N, et al. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord J Psychiatry 2007;61:100-108
45. Demyttenaere K, Hemels ME, Hudry J, et al. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005;27:111-124
46. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23:155-167